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Abstract
Background: Data from prospectively planned cohort studies on risk of major clinical outcomes and prognostic factors for
patients with influenza A(H1N1)pdm09 virus are limited. In 2009, in order to assess outcomes and evaluate risk factors for
progression of illness, two cohort studies were initiated: FLU 002 in outpatients and FLU 003 in hospitalized patients.
Methods and Findings: Between October 2009 and December 2012, adults with influenza-like illness (ILI) were enrolled;
outpatients were followed for 14 days and inpatients for 60 days. Disease progression was defined as hospitalization and/or
death for outpatients, and hospitalization for .28 days, transfer to intensive care unit (ICU) if enrolled from general ward,
and/or death for inpatients. Infection was confirmed by RT-PCR. 590 FLU 002 and 392 FLU 003 patients with influenza A
(H1N1)pdm09 were enrolled from 81 sites in 17 countries at 2 days (IQR 1–3) and 6 days (IQR 4–10) following ILI onset,
respectively. Disease progression was experienced by 29 (1 death) outpatients (5.1%; 95% CI: 3.4–7.2%) and 80 inpatients
[death (32), hospitalization .28 days (43) or ICU transfer (20)] (21.6%; 95% CI: 17.5–26.2%). Disease progression (death) for
hospitalized patients was 53.1% (26.6%) and 12.8% (3.8%), respectively, for those enrolled in the ICU and general ward. In
pooled analyses for both studies, predictors of disease progression were age, longer duration of symptoms at enrollment
and immunosuppression. Patients hospitalized during the pandemic period had a poorer prognosis than in subsequent
seasons.
Conclusions: Patients with influenza A(H1N1)pdm09, particularly when requiring hospital admission, are at high risk for
disease progression, especially if they are older, immunodeficient, or admitted late in infection. These data reinforce the
need for international trials of novel treatment strategies for influenza infection and serve as a reminder of the need to
monitor the severity of seasonal and pandemic influenza epidemics globally.
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Introduction
The emergence of influenza A(H1N1)pdm09 virus in 2009
highlighted the importance of having infrastructures in place to
conduct research that would inform patient management on
emerging viruses [1]. Although surveillance systems for influenza
exist in many parts of the world, these systems tend to be either
laboratory-based, focused on characterizing circulating virus
strains for vaccine strain selection or antiviral resistance monitor-
ing, or include clinical data on outpatients or hospitalized patients,
but do not include follow-up [2–6].
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Follow-up studies of patients diagnosed with influenza are
necessary to estimate the percentage that progress to death or
respiratory failure, or who require prolonged hospitalization.
Clinical data close to the time of diagnosis are needed to study risk
factors for progression. Ideally, such data would be available from
geographically diverse settings over several influenza seasons with
different influenza viruses in order to understand changing
patterns of disease and risk factors of progression. These data
could inform clinical management strategies as well as the design
of intervention studies.
In response to the urgent need for such follow-up data, in 2009
the National Institutes of Health funded two international cohort
studies of patients with A(H1N1)pdm09 virus infection. In this
report, we describe outcomes of outpatients and hospitalized
patients with influenza A(H1N1)pdm09 virus infection and
examine risk factors for progression of their illness. To our
knowledge, other global cohort data which include a follow-up
period, from geographically diverse settings for patients with a
broad range of severity of illness at the time enrollment do not
exist.
Methods
The International Network for Strategic Initiatives in Global
HIV Trials (INSIGHT) rapidly initiated two international cohort
studies of patients with A(H1N1)pdm09 virus infection in 2009.
Although originally designed to conduct large HIV treatment
trials, INSIGHT adapted and expanded its global network to
include the study of influenza. One study (FLU 002) enrolled
patients seeking assessment for influenza-like illness (ILI) as
outpatients; a second study (FLU 003) enrolled patients who had
been hospitalized for complications associated with influenza. The
study designs of both studies have been described elsewhere [7].
Briefly, the two studies were designed to cover a broad clinical
spectrum of A(H1N1)pdm09 virus infection in adults ($18 years of
age), ranging from outpatients presenting with mild ILI symptoms
(FLU 002) to those with more serious disease requiring hospital-
ization (FLU 003), and both studies included follow-up periods.
Initially, sites were not open to enrollment until A(H1N1)pdm09
virus was circulating in their geographic areas. Later these studies
were expanded to include other seasonal influenza viruses;
outcomes for patients with other influenza viruses will be included
in a subsequent report.
For both studies, information collected at the time of enrollment
included patient demographics, height, weight and vital signs; date
of ILI onset; medical history, including underlying conditions,
pregnancy status, and smoking history, and use of neuraminidase
inhibitors to prevent or treat influenza. For FLU 003, the type of
complication prompting hospital admission was also collected.
Ethics Statement
The FLU 002 and FLU 003 protocols were approved by the
institutional review boards (IRB) or institutional ethics committees
(IEC) at the University of Minnesota and at each of the
participating clinical sites worldwide (see Appendix S1). Written
documentation of IRB/IEC approval to each site Principal
Investigator was a required element in the site registration process
that preceded site activation as a study center. Copies of these
approval letters are filed with the central coordinating center at the
University of Minnesota. All patients (or proxy) gave signed
informed consent prior to enrollment.
Disease Progression Outcomes
Enrolled outpatients with ILI were followed for 14 days for
hospitalization or death. Henceforth for FLU 002 patients, this
composite outcome is referred to as ‘‘disease progression’’. At 14
days the resolution of symptoms was also assessed.
Enrolled hospitalized patients were followed for 60 days. For
general ward patients, outcomes assessed included death, ICU
admission and/or mechanical ventilation, or prolonged hospital-
ization; the latter was defined as an inpatient stay exceeding 28
days of the 60-day follow-up period, not necessarily consecutively.
For patients enrolled after ICU admission, death or prolonged
hospitalization for .28 days were the primary outcomes. For FLU
003 patients, this composite outcome, stratified according to
whether patients were enrolled from a general ward or ICU, is
referred to as ‘‘disease progression’’. Length of hospitalization,
resolution of symptoms, and resumption of normal activities were
assessed at 28 and 60 days after enrollment.
Methods for the Laboratory Diagnosis of A(H1N1)pdm09
virus infection
In both studies, respiratory (nasal and oropharyngeal) swabs
were collected at enrollment for influenza testing. The combined
respiratory sample was sent to one of two central laboratories for
influenza testing (SAIC Frederick, Inc, Maryland or Advanced
BioMedical Laboratories, New Jersey) by reverse transcription
polymerase chain reaction (RT-PCR) assay using specific primers
and probes for detection of influenza A, (seasonal H1,
H1N1pdm09, H3), and B viruses. In FLU 003, a local RT-PCR
test result was required either prior to enrollment (for confirmed
diagnoses) or at the time of enrollment (for suspected diagnoses).
Initially, local RT-PCR test results were only recorded as influenza
A positive or negative; after the first year, influenza A subtyping
results were recorded. We assessed the discordance of local and
central RT-PCR results. Results are shown in Appendix S2 with a
rationale for inclusion of patients in each A(H1N1)pdm09 virus-
infected cohort.
Definition of A(H1N1)pdm09 Virus-Infected Cohorts
Based on RT-PCR Results
Outpatients enrolled with A(H1N1)pdm09 confirmed at the
central laboratories are included in the FLU 002 cohort. The FLU
003 hospitalized cohort includes patients with A(H1N1)pdm09
virus infection confirmed at a central laboratory and patients who
tested positive for influenza A by a local laboratory and negative
for influenza A at a central laboratory during the initial 6 months
of enrollment when A(H1N1)pdm09 virus was highly prevalent
and the results of local RT-PCR testing did not record the
influenza A subtype (see Appendix S2).
Co-Pathogen Substudy
In a random subsample of 333 patients with A(H1N1)pdm09
virus infection, a tandem multiplex PCR (AusDiagnostics, Sydney
Australia) was performed on upper respiratory specimens to
estimate the prevalence of potential co-pathogens in each study
[8]. These laboratory analyses were performed at the Centre for
Infectious Diseases and Microbiology Laboratory Services,
Westmead Hospital, Westmead, New South Wales, Australia.
Statistical Analyses
Descriptive statistics were used to describe the characteristics of
patients enrolled in the two cohort studies. Cross-sectional
comparisons of patients in the two studies were performed to
assess factors potentially contributing to disease severity: odds
Clinical Outcomes of A(H1N1)pdm09 Infection
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ratios (ORs) (hospitalized patients versus outpatients) and 95%
confidence intervals (CIs) are cited. Unadjusted (univariable) and
adjusted (multivariable) ORs are cited. Similar analyses were done
for the subsample of patients for whom tandem multiplex PCR for
other pathogens was performed.
The percentage of patients developing disease progression
during follow-up was computed for each study. In addition,
cumulative mortality for patients in FLU 003 is summarized with
Kaplan-Meier plots. For these analyses, follow-up was censored at
the end of follow-up (60 days) or the date of last contact (e.g.,
discharge or day 28) for those who did not complete the full follow-
up. Logistic regression was used to study baseline predictors of
disease progression and mortality. Prognostic factors for disease
progression were determined separately for the two studies and for
pooled data from the two studies. Unadjusted and adjusted ORs
are cited along with 95% CIs and p-values. In expanded models,
an interaction term (covariate x study) was included in the logistic
model to assess whether associations with disease progression
differed for FLU 002 and FLU 003.
Height and weight data, used to determine body mass index
(BMI), were available for 91.0% of those enrolled. Date of onset of
symptoms for ILI and smoking prevalence data were available for
98.7% and 99.2% of enrolled patients respectively. Other baseline
covariate data were present for all patients. To minimize bias and
increase power for multiple regression analyses that require
complete covariate information for each patient, multiple impu-
tation was used to predict values that were substituted for the
missing data. The imputation was done in an iterative manner
using the baseline covariate data available. The regression
coefficients from five rounds of imputation were used to obtain
the ORs. The imputation had little effect on the univariable
analyses, therefore summary statistics from these analyses are
based on the observed data. In a sensitivity analysis, a complete
case analysis was performed and adjusted ORs were estimated for
all of the baseline variables excluding BMI. Estimates similar to
those based on multiple imputation were obtained (data not
shown).
All statistical tests are two-tailed and p-values less than 0.05
were considered to indicate statistical significance. Statistical
analyses were performed using SAS (Version 9.3).
Results
Between October 2009 and December 2012, 2,602 patients
were enrolled as outpatients in FLU 002, among whom 590 (23%)
had laboratory-confirmed A(H1N1)pdm09 virus infection
(Figure 1). Most (75%) patients with A(H1N1)pdm09 virus
infection in FLU 002 were enrolled between October 2009 and
September 2010 (Table 1) due to the declining prevalence of
A(H1N1)pdm09 virus after 2010. During October 2009 through
September 2010, 442 (94%) of 469 patients with a RT-PCR
diagnosis of influenza at a central laboratory had A(H1N1)pdm09
virus infection (data not shown). The prevalence of
A(H1N1)pdm09 virus over the next two years was 29% (119 of
410 patients) for patients enrolled between October 2010 and
September 2011 and 9% (29 of 316 patients) for those enrolled
between October 2011 and December 2012. After September
2010, A (H3N2) virus became the predominant influenza virus
identified (data not shown).
In FLU 003, 749 hospitalized patients were enrolled and 392
(52%) had laboratory-confirmed A(H1N1)pdm09 virus infection.
In both FLU 002 and FLU 003, most of the patients excluded
from this analysis had tested negative for influenza A and/or B
(Figures 1 and 2).
Baseline Characteristics of Patients with A(H1N1)pdm09
Virus Infection Enrolled in FLU 002
In FLU 002, outpatients with A(H1N1)pdm09 virus infection
were enrolled by 53 sites in 15 countries (see Acknowledgements
for number enrolled by country). Asian sites enrolled 20.3% of
patients; 4.1% of patients were from Australia; 46.1% from
Europe; 8.0% from South America; and 21.5% from the United
States. The median age of enrolled outpatients with
A(H1N1)pdm09 virus infection was 30 years; those enrolled in
the first year (2009–2010) had a median age that was 6 years
younger than in subsequent periods (29 versus 35 years; p,0.001
for difference) (Table 1). Fifty-two percent of patients were female;
1.9% had a BMI of $40 kg/m2; 21% reported smoking; and 2%
of the women aged #45 years of age were pregnant at the time of
enrollment or within the previous two weeks. Median time from
the onset of symptoms to enrollment was two days; for 75% of
patients this time was three days or less. Fifty-five patients (9.3%)
had HIV infection or other immune dysfunction; 50 of the 55
patients had HIV infection, reflecting the fact that many of the
infectious disease clinics participating in FLU 002 cared for
patients with HIV infection. Fifteen (2.5%) patients were
prescribed influenza antivirals (all oseltamivir) in the 14 days
prior to enrollment. On the day of enrollment, 28% of patients
were prescribed antiviral treatment (data not shown).
Disease Progression and Other Outcomes for Patients
with A(H1N1)pdm09 Virus Infection Enrolled in FLU 002
Disease progression status at day 14 was available for 572
(96.9%) of enrolled patients in FLU 002. Twenty-nine patients
(5.1%; 95% CI: 3.4–7.2%) experienced disease progression during
the 14-day follow-up period; 28 (4.9%) required hospitalization
and one patient died (Table 2). Of the 28 patients initially enrolled
as outpatients who were subsequently hospitalized, 12 (42.9%)
were admitted to the hospital later on the same day as study
enrollment.
One hundred and five outpatients (18.3%; 95% CI 15.2 to
21.7%) with A(H1N1)pdm09 virus infection reported that their
symptoms had not resolved by day 14; the percentage who died,
were hospitalized, or continued to report symptoms at day 14 was
22.2% (95% CI: 18.9 to 25.8%).
Baseline Characteristics of Patients with A(H1N1)pdm09
Virus Infection Enrolled in FLU 003
In FLU 003, hospitalized patients with A(H1N1)pdm09 virus
infection were enrolled at 56 sites in 16 countries; sites in 15 of
these countries also enrolled patients in FLU 002 (enrollment by
country is given in Acknowledgments). Asian sites enrolled 7.1% of
patients; 10.5% of patients were from Australia; 70.4% from
Europe; 2.0% from South America; and 10.0% from the United
States. Fifty-five percent were enrolled between October 2009 and
September 2010 (Table 3). Three hundred and seven (78.3%) of
the 392 A(H1N1)pdm09 patients were enrolled from a general
hospital ward and 85 (21.7%) were enrolled from an ICU. The
median age of hospitalized patients with A(H1N1)pdm09 was 48
years; those enrolled in the first calendar year of enrollment had a
median age that was seven years younger (44 versus 51 years;
p = 0.001 for difference) than in subsequent years. This age
difference was evident both for patients enrolled from the general
ward and from the ICU. Fifty-one percent of patients were female;
11% were Asian, 4% were black, and 85% were white/other; the
median BMI was 26 kg/m2; 5.3% had a BMI of $40 kg/m2; 30%
reported smoking; and 25% of the women aged #45 years were
pregnant. Fifty-three patients (13.5%) had HIV infection or other
Clinical Outcomes of A(H1N1)pdm09 Infection
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immune dysfunction; 14 of the 53 patients had HIV infection.
Median time from the onset of symptoms to enrollment was five
days for patients enrolled in the general ward and 10 days for
patients enrolled from an ICU. Eighteen patients (4.7%) developed
ILI symptoms after being hospitalized for some other condition;
the median (IQR) time between admission and ILI symptom onset
Figure 1. FLU 002 flow diagram.
doi:10.1371/journal.pone.0101785.g001
Table 1. Baseline characteristics of A(H1N1)pdm09-infected participants enrolled in FLU002.
Season of enrollment Oct 2009-Sep 2010 442 (74.9%)
Oct 2010-Sep 2011 119 (20.2%)
Oct 2011-Dec 2012 29 (4.9%)
Age - median (IQR) All patients 30 (24, 42)
Oct 2009-Sep 2010 enrollment 29 (23, 39)
Oct 2010-Dec 2012 enrollment 35 (28, 47)
Gender Female - no. (%) 307 (52.0%)
Race/ethnicity Asian - no. (%) 172 (29.2%)
Black - no. (%) 34 (5.8%)
White/other - no. (%) 390 (66.1%)
Influenza vaccine** All patients 82 (14.0%)
Oct 2009-Sep 2010 enrollment 63 (14.3%)
Oct 2010-Dec 2012 enrollment 19 (13.0%)
Other baseline characteristics BMI - median (IQR) 23.7 (21.3, 27.5)
BMI$40 kg/m2 - no. (%) 10 (1.9%)
Smoker - no. (%) 121 (20.6%)
Pregnant * - no. (%) 5 (2.0%)
Days since symptom onset - median (IQR) 2 (1, 3)
Medical history Antivirals in past 14 days - no. (%) 15 (2.5%)
Asthma/COPD - no. (%) 40 (6.8%)
Diabetes - no. (%) 12 (2.0%)
CVD/liver/renal disease - no. (%) 13 (2.2%)
HIV/other immune dysfunction - no. (%) 55 (9.3%)
*Currently or within previous 2 weeks, percent of women #45 years.
**Receipt of influenza vaccine during current season.
doi:10.1371/journal.pone.0101785.t001
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was 8 days (IQR: 5–18). Excluding the patients who likely
acquired A(H1N1)pdm09 virus infection in the hospital, the
median time from admission to enrollment was two days for
patients enrolled from a general ward and 5 days for patients
enrolled while in an ICU.
As would be expected, by most measures of disease severity
assessed (medical history, complications defining eligibility, and
other complications) patients enrolled in the ICU had more severe
illness than those enrolled from the general ward. Exceptions were
a history of asthma/chronic obstructive pulmonary disease
(COPD), cardiovascular disease (CVD), liver or renal disease,
and exacerbations of other co-morbidities which were more
common among patients enrolled from a general ward than those
enrolled from an ICU.
Two hundred and fifty-eight patients (65.8%) reported taking
antivirals for influenza in the 14 days prior to enrollment; 256
were taking oseltamivir and 5 were taking zanamivir (3 following a
course of oseltamivir). For patients taking an antiviral before
enrollment, 46.6% reported starting antiviral treatment within 3
days of the onset of ILI symptoms; the median time between
symptom onset and starting antiviral treatment was four days
(IQR: 2–7).
Disease Progression and Other Outcomes for Patients
with A(H1N1)pdm09 Virus Infection Enrolled in FLU 003
Disease progression status was known at day 60 for 370 (94.4%)
patients enrolled in FLU 003 (Figure 2). During the 60-day follow-
up period, 80 (21.6%; 95% CI: 17.5 to 26.2%) patients developed
disease progression; for those enrolled in the general ward and
ICU, 37 (12.8%; 95% CI: 9.2 to 17.2%) and 43 (53.1%; 95% CI:
41.7 to 64.3%) patients experienced disease progression, respec-
tively (Table 4).
Thirty-two patients (8.7%; 95% CI: 6.1 to 12.1%) died during
the 60-day follow-up period. Twenty seven of these 32 patients
died before discharge from the hospital at which they were
enrolled. Figure 3 shows Kaplan-Meier plots for all-cause
mortality for those enrolled in the general ward and the ICU.
Cumulative mortality at 14, 28 and 60 days for those enrolled
from a general ward were 2.3, 2.7, and 3.7%; for those enrolled
from an ICU, these percentages were 9.4, 19.2, and 25.6%,
respectively (95% CIs are given in the legend of Figure 3).
The number of days hospitalized since the time of enrollment,
taking into account re-admissions (49 patients had at least one re-
admission), was 5 days (IQR 2–12); for general ward patients the
median number was 4 days (IQR 1–8) and for those enrolled from the
ICU the median number was 15 days (IQR 8–32). For the estimation
of these medians, deaths were assigned a worst-case time of 60 days.
At 28 days of follow-up among 289 surviving patients who had
been discharged and attended the follow-up visit, 25.3% (95% CI:
20.3 to 30.7%) indicated that influenza symptoms had not
resolved; 38.5% (95% CI; 30.3 to 46.7%) of patients had not
resumed normal activities. At 60 days of follow-up among 292
surviving patients who had been discharged and attended the
follow-up visit, 14.7% of patients (95% CI: 10.7 to 19.3%)
indicated that symptoms had not resolved; 24.3% (95% CI: 17.4 to
32.2%) indicated that they had not resumed normal activities.
Comparison of Baseline Characteristics for FLU 002 and
FLU 003 Patients with A(H1N1)pdm09 Virus Infection
Table 5 summarizes the differences between FLU 002 and FLU
003 patients. In multivariable analyses, compared to outpatients,
Figure 2. FLU 003 flow diagram.
doi:10.1371/journal.pone.0101785.g002
Table 2. Outcomes through 14 days of follow-up for
A(H1N1)pdm09-infected patients enrolled in FLU002.
No. Pct. 95% CI
Death 1 0.17 0.0–1.0
Hospitalized during follow-up 28 4.9 3.3–7.0
Death or hospitalization (disease progression) 29 5.1 3.4–7.2
Death, hospitalization, or influenza symptoms 127 22.2 18.9–25.8
doi:10.1371/journal.pone.0101785.t002
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hospitalized patients were older, more likely to be female, have a
history of asthma or COPD, and a history of CVD, liver or renal
disease, and based on linear trend, have greater BMI and a longer
duration of symptoms (p,0.05 for all). In addition, in the first year
significantly fewer hospitalized patients were enrolled.
We also assessed whether pregnant women were more likely to
be enrolled in FLU 003 than FLU 002. Among women aged #45
years, there were more pregnant women in FLU 003 than in FLU
002 (see Tables 1 and 2) (univariable OR = 16.0; 95% CI: 5.9 to
43.1). After covariate adjustment, this OR was 32.5 (95% CI: 8.9
to 118.6).
Figure 4 gives the frequency distribution of the number of days
between the development of A(H1N1)pdm09-related symptoms
and enrollment for patients in FLU 002 and FLU 003. This
graphical depiction illustrates the longer period of time between
symptom onset and enrollment for patients in FLU 003. Also, for
those in FLU 003 for whom central laboratory RT-PCR results
were negative, but with positive results for A(H1N1)pdm09 virus
infection by a local laboratory, this time was even longer than for
those with centrally confirmed A(H1N1)pdm09 virus infection in
FLU 003(median time between illness onset and enrollment for
these patients was 10 days; IQR: 6–15). Overall, there was a
median of 2 (IQR: 1–4) days between local and central swab
collection (see Appendix S2).
The prevalence of other co-pathogens was compared for a
subsample of respiratory specimens for 235 patients in FLU 002
and 98 patients in FLU 003 (bottom of Table 5). With the
exception of S. aureus, which was more common in FLU 002 than
Table 3. Baseline characteristics of A(H1N1)pdm09-infected participants enrolled in FLU003.
FLU 003 Ward FLU 003 ICU Total
N = 307 N = 85 N = 392
Season of enrollment Oct 2009-Sep 2010 165 (53.7) 52 (61.2) 217 (55.4)
Oct 2010-Sep 2011 132 (43.0) 31 (36.5) 163 (41.6)
Oct 2011-Dec 2012 10 (3.3) 2 (2.4) 12 (3.1)
Age - median (IQR) All patients 48 (36, 60) 46 (31, 56) 48 (35, 59)
Oct 2009-Sep 2010 44 (34, 56) 40 (28, 57) 44 (32, 56)
Oct 2010-Dec 2012 51 (36, 62) 48 (40, 56) 51 (38, 62)
Gender Female - no. (%) 163 (53.1) 37 (43.5) 200 (51.0)
Race/ethnicity Asian - no. (%) 28 (9.1) 14 (16.5) 42 (10.7)
Black - no. (%) 14 (4.6) 3 (3.5) 17 (4.3)
White/other - no. (%) 265 (86.3) 68 (80.0) 333 (84.9)
Other baseline characteristics BMI - median (IQR) 25.6 (22.9, 30.0) 27.3 (24.8, 31.7) 26.0 (23.1, 30.4)
Smoker - no. (%) 97 (31.7) 19 (23.5) 116 (30.0)
Pregnant * - no. (%) 15 (18.3) 11 (50.0) 26 (25.0)
Days since symptom onset - median (IQR) 5 (3, 8) 10 (6, 14) 6 (4, 10)
Antiviral drugs in previous 14 days - no. (%) 192 (62.5) 66 (77.6) 258 (65.8)
Influenza vaccine** All patients 70 (23.8) 9 (13.6) 79 (21.9)
Oct 2009-Sep 2010 36 (22.5) 4 (11.1) 40 (20.4)
Oct 2010-Dec 2012 34 (25.4) 5 (16.7) 39 (23.8)
Medical History Asthma/COPD - no. (%) 91 (29.6) 13 (15.3) 104 (26.5)
Diabetes - no. (%) 27 (8.8) 12 (14.1) 39 (9.9)
CVD/liver/renal disease - no. (%) 61 (19.9) 15 (17.6) 76 (19.4)
HIV/other immune dysfunction - no. (%) 43 (14.0) 10 (11.8) 53 (13.5)
Complications Defining Eligibility Supplemental oxygen required - no. (%) 239 (77.9) 81 (95.3) 320 (81.6)
Exacerbation of comorbidity - no. (%) 120 (39.1) 18 (21.2) 138 (35.2)
Vasopressors required - no. (%) 10 (3.3) 28 (32.9) 38 (9.7)
Acute renal failure - no. (%) 14 (4.6) 19 (22.4) 33 (8.4)
Acute liver failure - no. (%) 6 (2.0) 2 (2.4) 8 (2.0)
Pregnancy complications - no. (%) 5 (1.6) 5 (5.9) 10 (2.6)
Other organ dysfunction - no. (%) 15 (4.9) 7 (8.2) 22 (5.6)
Other Complications Bacterial pneumoniae - no. (%) 83 (27.0) 32 (37.6) 115 (29.3)
Dehydration requiring IV - no. (%) 92 (30.0) 34 (40.0) 126 (32.1)
Enteritis - no. (%) 13 (4.2) 8 (9.4) 21 (5.4)
Septicemia - no. (%) 7 (2.3) 8 (9.4) 15 (3.8)
*Currently or within previous 2 weeks, percent of women #45 years.
**Receipt of influenza vaccine during current season.
doi:10.1371/journal.pone.0101785.t003
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FLU 003 in univariable analysis but not in multivariable analyses,
the prevalence of potential co-pathogens in the upper respiratory
tract did not differ significantly between patients in the two studies.
Relationship of Baseline Factors with Disease Progression
for Patients in FLU 002 and FLU 003 with A(H1N1)pdm09
Virus Infection: a Pooled Analysis
Table 6 summarizes the association of baseline characteristics
with disease progression in pooled analyses of data for FLU 002
and FLU 003 patients. The same baseline characteristics
considered in the cross-sectional comparisons in Table 5 are
summarized. In the unadjusted analysis, in addition to enrollment
in the ICU, older age (median 48 years vs. 35 years), longer
duration of symptoms ($6 days versus ,4 days), diabetes, history
of CVD, renal or liver disease, and immunosuppression were
significantly associated with disease progression. In multivariable
analysis, enrollment in the ICU (OR 12.1, 95% CI 5.6 to 26.4; p,
0.001), age (OR = 1.22 per 10 years older, 95% CI: 1.02 to 1.45;
p = 0.03), duration of symptoms ($6 days versus ,4 days, OR
2.66, 95% CI 1.36 to 5.20; p = 0.004), and immunosuppression
(OR 2.20, 95% CI 1.17 to 4.13; p = 0.01) were associated with
disease progression.
An analysis was performed for female patients aged #45 years
with A(H1N1)pdm09 virus infection to investigate whether
pregnancy was associated with an increased risk of disease
progression. For this cohort of 336 women, among whom 29
developed disease progression, the unadjusted OR for disease
progression associated with pregnancy was 4.09 (95% CI: 1.57 to
10.6; p = 0.004). With covariate adjustment, this OR was reduced
and no longer significantly greater than one (OR = 1.61, 95%
CI:0.42 to 6.19).
Separate analyses were carried out for patients in each study
(data not shown). With few exceptions, the multivariable analyses
for each study were consistent with the pooled results. In both
studies, there was an increased risk of progression associated with
symptoms for 6 or more versus ,4 days (ORs 2.54 and 2.85 for
FLU 002 and FLU 003) and immunosuppression (ORs 4.04 and
1.99). Older age was not associated with progression in FLU 002
(OR = 0.95; p = 0.80) and was associated with an increased risk of
progression in FLU 003 (OR = 1.27; p = 0.02); however, the
difference in the ORs was not significant (p = 0.76). Asthma or
COPD was associated with a non-significant increased risk of
progression in outpatients (OR = 2.22; p = 0.21) and a significant
reduced risk of progression in hospitalized patients (OR = 0.35;
p = 0.01) (p = 0.005 for difference in ORs). Among women aged #
45 years, pregnancy was associated with an increased risk of
progression in FLU 002 (OR = 30.1; p = 0.015) and was not
associated with disease progression in FLU 003 (OR = 0.88;
p = 0.89) (p = 0.07 for difference in ORs). In outpatients, there was
an increased risk of progression for those enrolled during the first
year (OR = 12.3; p = 0.02); this was not evident for inpatients
(OR = 0.83; p = 0.57) (p = 0.06 for differences in ORs). The
associations of other baseline factors considered with disease
progression did not differ for FLU 002 and FLU 003 patients.
We also examined predictors of mortality during the 60-day
follow-up in patients enrolled in FLU 003 (Table 7). In univariable
analyses in addition to enrollment in the ICU, Asian race,
duration of symptoms $6 days, and a history of diabetes were
associated with an increased risk of death. In multivariable
analyses, Asian race (p = 0.01) and duration of symptoms (p = 0.03)
remained significant predictors. There was also evidence of a
higher risk of death for those with immunosuppression (p = 0.03)
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Discussion
In two international cohort studies of patients with
A(H1N1)pdm09 virus infection, one in outpatients and the other
in hospitalized patients, we estimated the risks of disease
progression using several clinical outcomes. These estimates of
disease progression, together with factors that influenced the risk of
progression are useful considerations in designing studies aimed at
the prevention and treatment of influenza infection, and planning
for future epidemics. Many of the clinical outcomes we assessed
have been considered in guidance from the Food and Drug
Administration and were discussed at an NIH workshop [9,10].
We found that 5% of patients seeking outpatient care required
hospitalization within 14 days; almost one-half of the patients
requiring hospitalization were admitted on the same day that they
sought outpatient care. At 14 days, 18% of outpatients still had
influenza symptoms. Other studies have also indicated that
symptoms of influenza can last for many days. A prospective
study conducted in the UK of 186 patients that had confirmed
A(H1N1)pdm09 virus infection reported that the average duration
of symptoms was 8.8 days (range 1–28 days), the average time off
from work was 7.3 days (range 1–28 days), and the overall quality
adjusted life days lost was 2.92 (range 0–9.84, median 2.18) [11].
In FLU 003, 13% of patients enrolled in the general ward and
53% of patients enrolled in the ICU had experienced disease
progression by 60 days; mortality at 60 days was 4% and 27% for
those enrolled in the general ward and ICU, respectively. At 60
days of follow-up among 288 surviving patients who were not in
the hospital, 14.7% of patients (95% CI: 10.7 to 19.3%) indicated
that symptoms had not resolved. There are a few other studies for
which comparable results were reported, some such as reports on
surveillance systems did not have a follow-up period and reported
on deaths during hospitalization. In a World Health Organization
study, Van Kerkhove, et al. reported on surveillance from
Ministries of Health or National Public Health Institutes of 19
countries or administrative regions that encompassed 70,000
laboratory-confirmed A(H1N1)pdm09 hospitalized patients during
April 2009-January 1, 2010. There were 9,700 (13.9%) patients
admitted to the ICU and 2,500 (3.6%) deaths [6]. Active
surveillance for laboratory-confirmed A(H1N1)pdm09 virus infec-
tion in ten U.S. states during April 2009-April 2010 found that 4%
of 5238 hospitalized adults died during the hospitalization [12]. A
review by Cheng using 18 published reports found that the case
fatality proportion for hospitalized patients with laboratory-
confirmed A(H1N1)pdm09 infection varied by region (Asia,
Europe, Oceania, South America and North America) and ranged
from 1.6% (Asia) to 6.9% (North America) [13]. In FLU 003, the
majority of deaths (27 of 32) occurred in the hospital where the
patient was enrolled. The 60-day mortality we observed among
patients who were enrolled in the ICU (27%) is similar to reports
by Rice and Brun-Buisson [14,15]. Rice reported a 60-day
mortality of 23% for 683 patients with confirmed or probable
A(H1N1)pdm09 virus infection who were enrolled in ICUs in the
United States. Brun-Buisson reported a study of 208
A(H1N1)pdm09 virus-infected patients in France with acute
respiratory distress syndrome: 49 (24%) had died by 60 days
following the initiation of mechanical ventilation. Kumar followed
patients for 90 days and reported that among 168 critically ill
patients (including 50 children) in Canada with A(H1N1)pdm09
virus infection, 29 (17.3%) patients died, including 4 children; 18
(10.7%) patients died within 14 days and 24 (14.3%) died within
28 days of critical illness onset [16]. The ANZIC Influenza
Investigators reported on 722 patients with confirmed
A(H1N1)pdm09 admitted to an ICU in Australia and New
Zealand during June through August, 2009. The median duration
of ICU stay was 7 days and 16.9% patients died in the hospital
[17].
One of the notable observations associated with
A(H1N1)pdm09 virus-infected patients has been that younger
adult populations were affected more frequently than what is
usually observed for seasonal influenza [6,13,16–23]. The median
age of outpatients and inpatients in our two cohorts were 30 and
Figure 3. Cumulative percentage of patients with death from any cause in FLU 003 according to location of enrollment. The number
of patients at risk at each timepoint are given below the graph.
doi:10.1371/journal.pone.0101785.g003
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48 years, respectively. For both cohorts, the median age
significantly increased after the first year. This is consistent with
other reports [24,25].
Our data suggest that morbidity and mortality during the initial
season of enrollment was greater than in subsequent calendar
periods after adjustment for the age difference. Consistent with
this, using surveillance systems in Canada, Helferty reported a
decline in admissions in the second wave of the epidemic [24].
Interestingly, a study from Spain, reported by Martin-Loeches,
found a higher mortality during the post-pandemic period
compared to the pandemic period; however, their analysis did
not take into account the older age of patients in the post-
pandemic period [25].
Our analyses also identify potential problems interpreting
results from cross-sectional studies comparing outpatients and
inpatients. For example, hospitalized patients were more likely to
have greater BMI than outpatients; however, BMI was not
associated with a risk of progression in the cohort analyses. The
finding from the cross-sectional analyses may reflect the popula-
tion of people that are hospitalized rather than be predictors of
severe influenza. Similarly, women of child-bearing age who were
pregnant were more likely to be enrolled in FLU 003 and were
more likely to be hospitalized if enrolled in FLU 002. These data
may reflect a reduced threshold for hospitalizing pregnant women
with influenza infection because of concern about the development
of disease progression. Similar findings were noted for patients
with asthma or COPD. Cross-sectional differences and the
apparent different associations with progression in FLU 002 and
FLU 003 likely reflect a propensity for hospitalizing patients with
these conditions when they develop ILI.
Longer duration of symptoms and immunosuppression were
associated with an increased risk of disease progression in our
study. In a previous report, we also found that markers of
inflammation and coagulation were associated with an increased
risk of progression [26]. Other reports have found a number of
factors associated with severity of disease that include underlying
chronic medical conditions, immunosuppression (including HIV if
advanced immunosuppression), neurological disease, morbid
obesity and pregnancy [12,14,18–21,23–25,27–38]. Additionally,
longer duration between onset of symptoms and hospitalization
has been associated with an increased risk of death or severe
outcome [21,28]
In FLU 003, the median number of days from symptom onset to
enrollment was 5 days for those enrolled on the general ward and
10 days for those enrolled in an ICU. This delay in enrollment for
those with severe disease is relevant for the study of new treatments
as was pointed out in a recent clinical trial in Southeast Asia [39].
Approaches to expedite enrollment are important to consider
when planning such studies. The finding of hospital-acquired
infections emphasizes the need for influenza surveillance in the
hospital setting.
Bacterial co-infections, particularly causing pneumonia, have
been associated with increased severity of A(H1N1)pdm09 virus
infection in hospitalized patients [14,28]. Bacterial pneumonia was
a complication found in 29% of FLU 003 participants at
enrollment. Patients with influenza are thought to be at higher
risk for secondary bacterial infection and pneumonia because of
the cytopathic effects of viral replication in cells as well as
dysregulated changes in host cytokine production that may
diminish both the ability of the immune system to clear bacteria
and to achieve appropriate modulation of the inflammatory
cascade [40,41]. We assessed the prevalence of viral and bacterial
co-pathogens in a sample of 333 patients and did not find any
significant differences in prevalence or outcomes between FLU
002 and FLU 003 patients. In a cross-sectional study of 199
patients from Argentina with A(H1N1)pdm09 virus infection,
upper respiratory swabs were tested for a variety of bacterial and
viral potential pathogens. In that study S. pneumoniae was associated
with increased disease severity (it was detected among 25.0% of
patients seen at ambulatory clinics and 56.4% of patients who
were hospitalized or died) [42].
Figure 4. Frequency distribution of number of days between onset of ILI symptoms and enrollment for patients in FLU 002 and FLU
003.
doi:10.1371/journal.pone.0101785.g004
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Approximately 66% of patients reported taking neuraminidase
inhibitors (NAI) in the 14 days prior to enrollment. Of those taking
antivirals, less than half started these medications within three days
of illness onset. A recent meta-analysis of hospitalized patients
found a decreased mortality associated with early treatment
(within 48 hours of symptom onset) versus late treatment or no
treatment [43]. The authors of this meta-analysis point out that
sicker patients are more likely to receive antivirals and patients
with milder disease may not be treated, highlighting potential
confounders and limitations of observational studies.
A particular strength of our studies is that they are cohort
studies with well-defined follow-up periods for estimating disease
progression rates. Notably, a high proportion of enrolled patients
were available for follow-up evaluation (97% for FLU 002 and
94% for FLU 003). The cohorts include patients from 17
countries, incorporating a diverse population including varied
ethnicities and economies. Enrollment over a 3-year period
enabled evaluation in the time period after A(H1N1)pdm09 virus
emerged in 2009. Multiple clinical outcomes were assessed and
described after different follow-up intervals. These data should be
useful for planning intervention trials.
Of note, Ortiz and colleagues raised the concern that there is a
lack of clinical studies in the setting of a public health emergency
[such as the A(H1N1)pdm09 pandemic] to inform clinical care,
particularly in low-resource settings [44].
By utilizing an already existing clinical study infrastructure
through the INSIGHT network, we were able to rapidly develop a
system for studying the emergence of a novel influenza A virus and
clinical outcomes of infection in an international setting. We have
maintained this system to continue observational cohort studies to
assess clinical outcomes of seasonal influenza across diverse
geographic areas and patient populations, and to serve as a
platform for treatment studies. Further, the INSIGHT FLU
network is currently being adapted to include other emerging
respiratory viruses of global public health importance [e.g. MERS-
CoV, avian influenza A(H7N9) virus].
Our studies have a number of limitations including the relatively
small number of disease progression outcomes in the outpatient
cohort, thereby limiting their power. A recent meta-analysis aimed
at evaluating risk factors for severe outcomes in seasonal and
pandemic influenza found that the lack of power is an issue for
many studies [45]. At least a theoretical limitation is that there
may be possible misclassification in FLU 003 because of
potentially false positive RT-PCR results, particularly those with
a positive local laboratory result and a negative central laboratory
result. However, the false positive rate with commercial RT-PCR
assays is generally quite low. Rather, because some of these
individuals who had a positive local RT-PCR were enrolled more
than ten days after the onset of symptoms, a time at which they
may no longer be shedding influenza virus, the potential for
misclassification would have been greater if they had been
excluded.
In summary, our findings highlight the high frequency of disease
progression associated with A(H1N1)pdm09 virus infection on a
global basis, particularly in patients requiring hospital admission,
while also highlighting the potential hazards of cross-sectional
comparisons according to level of severity. Observational studies
such as FLU 002 and FLU 003 that employ specified periods of
clinical follow-up are absolutely critical in properly assessing
disease progression and associated risk factors. Our experience will
be useful in planning additional observational studies of emerging
novel influenza A viruses and novel emerging respiratory viruses,
and the data from FLU 002 and FLU 003 will help inform the
design of interventional studies of new antiviral medications and
other strategies for the treatment and prevention of influenza
infection.
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